News

16.01.2023 FDA no longer has to require animal tests before human trial

The year 2023 is starting with positive news after the U.S. Congress passed the FDA Modernization Act 2.0, which removes the requirement for animal testing in drug development. The decision paves the way to finally allowing the use of data generated from new alternative methods (NAMs), such as abc biopply's 3D multi-organoid in chip assays. (review our Newsletter here...)

08.12.2022 Dr. Olivera Evrova joints abc biopply

We are pleased to welcome Dr. Olivera Evrova as a new member to our abc biopply team. Olivera will strengthen our laboratory group in the execution of preclinical study projects and the further development of our 3D assay portfolio.

04.11.2022 - Festival of Biologics 2022, Basel

abc biopply enjoyed a very successful participation at the Festival of Biologics 2022 in Basel, Switzerland. A big thank you to all our customers and potential partners for the enthusiastic feedback on our microphysiological preclinical disease models and assays. See you in San Diego.

WE ARE HIRING - Research and Development Scientist 100% (m/f)

Cham, 27.10.2022 Are you interested to become a key member of our dynamic and motivated abc biopply team and work cross-functionally to support our customers and research partners? Interested? Contact us today! More information here...

04.10.2022 - Press Review: abc biopply in DrugDiscovery online

Read the most recent article in DrugDiscovery online about abc biopply's activities by clicking here.

24.08.2022 - ReachBio and abc biopply Partner to Intensify Support for de-risking Pharma's Drug Development Process

20.08.2022 Seattle/Solothurn Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their clients with an even more predictive assay portfolio to further increase the efficiency of their drug discovery and development services.

28.06.2022 – WEBINAR: A Novel 3D High Throughput Co-culture System for Multiple Myeloma

In collaboration with the American Physiological Society (APS) and our American partner nanoscaleLABS, abc biopply is organizing a webinar on the use of 3D CoSeedis™ in high throughput ex vivo propagation of multiple myeloma cells. Dr Johannes Waldschmidt and Dr Andreas Thomsen from the University of Freiburg in Germany together with Dr Marco Leu from abc biopply will discuss the importance of reliable 3D preclinical disease models in accurate and predictive compound testing.

08.02.2022 - abc biopply last year’s revenues up more than twice in its strategic core business

Solothurn 08.02.2022 Swiss Biotech Company abc biopply reports revenues in 2021 more than doubled in its core business with its preclinical 3D tumor models. The company has started offering these specialized CRO services to its biotech and pharma clients since 2019. Press Release

09.12.2021 - Making 3D cell culture a part of HTS standard applications

abc biopply and SEED Bioscienses have recently started to co-develop an inovative new method to make 3D cell cultures assessible for HTS applications. In this collaboration, abc biopply provides highly homogenous and uniform 3D cultures in large quantities using its prorietary 3D CoSeedis™ platform whereas SEED Bioscienses uses its DISPENCELL technology to disperse them into HTS compatible multi-well plates.

Finally, HTS users will gain access to a reliable source of high quality 3D cultures in sufficient quantities to reach unprecedented efficacy in HTS of 3D cultures.

01.04.2021 - 3D Cell Culture Market

We are very pleased to be one of the key players mentioned in the most recent 3D cell culture market report of IndustryARC. Download here the report preview.

17.03.2021 - abc biopply in the media

Please read the article on the startupticker.ch platform from 11.03.2021

12.03.2021 - New Partner in USA

3D CoSeedis™ is now also available in the United States.

05.03.2021 - abc biopply enters into a strategic partnership with Quadira Biosciences

abc biopply enters into a strategic partnership with Quadira Biosciences, to create a sustainable concept for the development of highly effective therapeutic antibodies without animal testing.

01.02.2021 - 3D CoSeedis™ shows outperforming results for the cultivation of homogeneous spheroids

Cooperation of abc biopply with CELLdynamics demonstrates that 3D CoSeedis™ outperforms conventional 3D cell culture systems in generating highly homogenous and uniform spheroids.

27.01.2021 - New Distribution Partner in Korea

Welcome to Chayon Laboratories – our new partner in Korea.

27.10.2020 - 3D CoSeedis™ in extracellular vesicle production

3D CoSeedis™ has been recommended as the tool of choice in the production of extracellular vesicles (EV) from 3D cultures. The chapter in Methods in Enzymology gives a detailed introduction into the isolation of EVs from highly homogenous and uniform 3D cultures using the 3D CoSeedis™ system.

02.10.2020 - New distribution partnership for Japan

Our international distribution network expands.

14.09.2020 - Webinar about the latest news on 17 September 2020

Sign up for the next webinar about the latest news about 3D CoSeedis™.

13.07.2020 - 3D CoSeedis™ - Mass Production of Homogeneous and Uniform Spheroids for HTS/HCS

A new white paper is available.

12.05.2020 - Book your time for a Webinar on 3D CoSeedis™

The webinar with our medical advisor Dr. Andreas Thomsen takes place on 14 May 2020.

24.04.2020 - 3D CoSeedis™: now available with a vast range of primary cells

3D CoSeedis™: the ideal 3D model to grow primary cells.

06.04.2020 - BioKé – our new distribution partner in BeNeLux

3D CoSeedis™ now available also in Belgium, Netherlands and Luxemburg.

23.01.2020 – abc biopply @ JPM conference in San Francisco

After many fruitful conversations in the USA we return home with a huge suitcase full of helpful information.

04.11.2019 - Product Launch 3D CoSeedis™ 0.5x0.5 format for 24-well plates

3D CoSeedis™ goes 24! Have a look at our new format of the 3D cell co-culture system.

25.10.2019 - Impressions from the TEDD annual meeting 2019

Thank you to our partners.

09.10.2019 - Lunch Time Seminar CMU Geneva

Special thanks to our Medical Advisor and Regina Rufener.

01.10.2019 - Thistle Scientific – Distributor in UK

abc biopply goes to the UK:. Thistle Scientific becomes abc biopply’s distribution partner in the UK.

19.09.2019 - ILMAC Basel 2019

Meet us at BioCocept's booth.

05.09.2019 - New application note assesses viability and cytotoxicity

The method can perform fluorescent based viability/cytotoxicity tests on spheroidal and non-spheroidal 3D constructs.

12.07.2019 - Colony forming assay with 3D CoSeedis™ used in Tspan8-Publication by I. Nazarenko

The authors made use of the 3D CoSeedis™ system to assess radiation resistance in 3D conditions via a colony forming assay (CFA).

13.06.2019 - 3D CoSeedis™: A new approach to the colony forming assay

A new publication on the colony forming assay in cancer research is available.

28.05.2019 - One day in the lab of abc biopply

The sales team of BioConcept, our partner in Switzerland, visited us and attended a training day about 3D CoSeedis™.

16.05.2019 – Lunchtime Seminar Lausanne

The talk about the unique microenvironments in 3D models has been a great success.

09.05.2019 - abc biopply introduces a new 3D CoSeedis™ Co-culture System

Our product family is growing.

29.03.2019 - 1st Symposium on Optimised Cancer Treatments with 3D Models

The symposium was a complete success.

11.03.2019 - Mini-Symposium: Optimised Cancer Treatments with 3D Models

Visit the symposium in Munich on 27 March 2019.

27.02.2019 - abc biopply and BioConcept: a strong partnership for the Swiss market

abc biopply is looking forward to working together with BioConcept on the success of 3D CoSeedis™.

01.02.2019 - abc biopply at the Centre Léon Bérard in Lyon, France

Visit us on 5 February 2019 in France and learn more about 3D CoSeedis™.

09.01.2019 - Extracellular Vesicles Composition Affected by 3D Cell Architecture

3D CoSeedis™ has recently been used in a study on extracellular vesicle composition.

07.01.2019 - abc biopply goes international

3D CoSeedis™ is now available in Germany, Austria, France and Canada.

07.12.2018 - 3D CoSeedis™: valuable 3D data in radiation therapy response

A new publication about 3D CoSeedis™ is available.

26.11.2018 - Partnership with AnaPath

abc biopply has developed a standardised way to conveniently embed 3D cell aggregates grown in the 3D CoSeedis™ matrix in paraffin for immunological analysis. In this context we haverecently also started a partnership with AnaPath.